A slightly down-regulation of CB1 gene expression in the cochlea and in the kidney was observed when animals received CDDP treatment, being statistically significant in the kidney probably due to a primary down-regulation trying to ameliorate tissue damage promoted by CB1 in nephropathy models [37]. This evidence concerns the gene CNR1 and kidney disorder.